At a glance
ClinicalIndex Comparison RecordPhase 3Recruiting· 506 target
Drug / intervention
cadonilimab +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-blind, Phase 3 Study Of Cadonilimab (AK104) Plus Pulocimab (AK109) And Paclitaxel Versus Paclitaxel In Patients With Advanced Gastric Or Gastroesophageal Junction Adenocarcinoma Who Failed First-line Immunochemotherapy
In Brief
A Phase 3 clinical trial evaluating cadonilimab, pulocimab, and 2 other interventions for Gastric and Gastroesophageal Junction Adenocarcinoma. Currently recruiting, targeting 506 participants across 1 site.
Detailed Summary
This randomized, multicenter, double-blind, phase 3 study will evaluate the efficacy and safety of the combination of cadonilimab (AK104) and pulocimab (AK109) and paclitaxel compared with paclitaxel in patients with advanced gastric or gastroesophageal junction adenocarcinoma who failed first-line immunochemotherapy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesChina
Collaborators--
Timeline
Phase 3Recruiting
202520262027
First PostedApr 2024
Enrollment StartJun 2024
TodayJul 2026
Primary CompletionNov 2026
Study CompletionJul 2027
First PostedApr 2, 2024
Enrollment StartJun 19, 2024
Primary CompletionNov 1, 2026
Study CompletionJul 1, 2027
TodayJul 1, 2026
Enrollment to primary: 2.4 yearsPosted 2.2 years agoPrimary completion in 4 months
Interventions
cadonilimabdrug
iv, q3w
pulocimabdrug
iv, q3w
paclitaxeldrug
iv, q3w
placebodrug
iv, q3w